Immunotech Biopharm Ltd

As of December 31, 2025, Immunotech Biopharm Ltd carries a market capitalization of 1.81B, placing it among publicly traded companies globally. Its enterprise value stands at 2.12B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Immunotech Biopharm Ltd's next confirmed earnings release is scheduled for March 19, 2027.

As of December 31, 2025, Immunotech Biopharm Ltd has 617.50M shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, Immunotech Biopharm Ltd maintains a current ratio of 0.35, meaning it holds 0.3x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on October 22, 2026, Immunotech Biopharm Ltd's stock has declined approximately 89.15% over the past 52 weeks. The 50-day moving average sits at 0.40, while the 200-day moving average is 1.43.

As of December 31, 2025, Immunotech Biopharm Ltd holds 172.02M in cash and equivalents against 489.96M in total debt, resulting in a net debt position of 314.24M. Total book value stands at -15.50M, with working capital of -355.30M providing operational flexibility.

Immunotech Biopharm Ltd's most recent stock split took place on October 2, 2025 with a 445:484 split ratio.